Analysis of influenza epidemics during the COVID-19 pandemic using an improved surveillance system (from 2021 to 2024) by Ludmila S. Karpova, Maria Yu. Pelikh, Kirill A. Stolyarov, Ksenia M. Volik, Tatyana P. Stolyarova, Daria M. Danilenko

“…In 2022–2023, the influenza A(H1N1)pdm09 and B epidemic was of moderate intensity in terms of incidence, with a high frequency of hospitalizations and mortality (120 cases). …”
Get full text

hnRNPH1 Inhibits Influenza Virus Replication by Binding Viral RNA by Ruixue Xue, Danqi Bao, Tianxin Ma, Shiqi Niu, Zihua Wu, Xuehua Lv, Yunxiang Zhang, Guanlong Xu, Dawei Yan, Zhifei Zhang, Xue Pan, Minghao Yan, Qiaoyang Teng, Chunxiu Yuan, Zejun Li, Qinfang Liu

“…The results showed that the host hnRNPH1 inhibits the replication of H1N1 and H9N2 influenza viruses by restraining the polymerase activity of viruses. hnRNPH1 contains two RNA recognition motifs (RRM1) and RRM2. …”
Get full text

Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine by Yongqiang Zhao, Jia Liu, Chun Peng, Shuangshuang Guo, Bo Wang, Longping Chen, Yating Wang, Haiwen Tang, Liming Liu, Qi Pan, Shiren Li, Jingyu Wang, Dongni Yang, Enqi Du

“…Intranasal vaccination with CHM-f nanoparticles elicited robust humoral and cellular immune responses, conferring complete protection against a variety of IAVs, including the A/PR8/34 H1N1 strain, the swine flu H3N2 strain, the avian flu H5N8 strain, and H9N2. …”
Get full text

Гострі респіраторні вірусні інфекції та грип у дітей: до, під час, після пандемії COVID-19 by N.V. Banadyha, I.O. Rogalskyy

“…., викликана вірусами A/H3N3, A/H3N2, A/H1N1 pdm09 і B, відповідно. У віковому аспекті основну групу становили діти віком до 5 років. …”
Get full text

Impact of COVID-19 pandemic measures on hospitalizations and epidemiological patterns of twelve respiratory pathogens in children with acute respiratory infections in southern Chin... by Wei Wang, Xiaojuan Luo, Zhenmin Ren, Xiaoying Fu, Yunsheng Chen, WenJian Wang, Yanmin Bao, Yuejie Zheng, Ke Cao, Jiehua Chen

“…RSV showed out-of-season epidemics for two consecutive years. Influenza A (H1N1), Influenza A (H3N2), and InfB lost their seasonal patterns during Phase 1 but reemerged and regained their seasonal characteristics in 2023–2024. …”
Get full text

Вірусні пневмонії в дітей: сьогодення і майбутнє by L.I. Chernyshova, A.V. Chernyshov

“…Після появи тяжкого гострого респіраторного синдрому (SARS), вірусу пташиного грипу A (H5N1) та вірусу пандемічного грипу A (H1N1) у 2009 р. особлива увага була привернута до важливої ролі респіраторних вірусів як причин тяжкої пневмонії. …”
Get full text

Portable UV-C device to treat high flow of infectious aerosols generated during clinical respiratory care by Richard Vincent, David Rapoport, Priti Balchandani, Joseph Borrello, Michael Schotsaert, Robert Karlicek, Gabriel Laghlali, Prajakta Warang, Seokchan Park, Gagandeep Singh, Isabella Morgan, James Paredes, Raveen Rathnasinghe, Jacob Wolf, Adolfo García-Sastre

“…Testing was with nebulized A/PR/8/34 (H1N1) influenza virus. RNA extraction and qRT-PCR showed virus transited through the prototype. …”
Get full text

The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections by Mohamed, Moubarak, Keneth Iceland, Kasozi, Helal F., Hetta, Hazem M., Shaheen, Abdur, Rauf, Hayder M., Al-kuraishy, Safaa, Qusti, Eida M., Alshammari, Emmanuel Tiyo, Ayikobua, Fred, Ssempijja, Adam Moyosore, Afodun, Ritah, Kenganzi, Ibe Michael, Usman, Juma John, Ochieng, Lawrence Obado, Osuwat, Kevin, Matama, Ali I., Al-Gareeb, Emmanuel, Kairania, Monica, Musenero, Susan, Christina Welburn, Gaber, El-Saber Batiha

“…For treatment, convalescent plasma therapy, successfully deployed during recent Ebola outbreaks and for H1N1 influenza, can increase survival rates and improve host responses to viral challenge. …”
Get full text

Targets of influenza human T-cell response are mostly conserved in H5N1 by John Sidney, A-Reum Kim, Rory D. de Vries, Bjoern Peters, Philip S. Meade, Florian Krammer, Alba Grifoni, Alessandro Sette

“…Based on these observations, and the overall similarity of the neuraminidase (NA) N1 subtype encoded in both HPAI and seasonal H1N1 influenza virus as well as cross-reactive group 1 HA stalk-reactive antibodies, we expect that a degree of pre-existing immunity is present in the general human population that could blunt the severity of human H5N1 infections.IMPORTANCEInfluenza A viruses (IAVs) cause pandemics that can result in millions of deaths. …”
Get full text

Adenoviral Vector-Based Vaccine Expressing Hemagglutinin Stem Region with Autophagy-Inducing Peptide Confers Cross-Protection Against Group 1 and 2 Influenza A Viruses by Wen-Chien Wang, Ekramy E. Sayedahmed, Marwa Alhashimi, Ahmed Elkashif, Vivek Gairola, Muralimanohara S. T. Murala, Suryaprakash Sambhara, Suresh K. Mittal

“…Among the tested combinations, Ad vectors expressing SP + HA stem + AIP-C5 conferred significant protection against group 1 (H1N1 and H5N1) and group 2 (H3N2) influenza A viruses. …”
Get full text

Rapid aging of influenza epidemics in China from 2005/06 to 2016/17: A population-based study by Weibo Tang, Hao Lei, Nan Zhang, Yaojing Wang, Shimeng Cai, Shuyi Ji, Lei Yang, Mengya Yang, Can Chen, Shigui Yang, Dayan Wang, Yuelong Shu

“…The aging of patients infected with influenza B/Yamagata was the most rapid, with a mean age increase of 0.73 years per year, followed by those infected with influenza A (H1N1) and influenza A (H3N2). Conversely, there was no significant increase in the mean age of patients infected with influenza B/Victoria. …”
Get full text

Hospital-Based Surveillance of Respiratory Viruses Among Children Under Five Years of Age with ARI and SARI in Eastern UP, India by Hirawati Deval, Mitali Srivastava, Neha Srivastava, Niraj Kumar, Aman Agarwal, Varsha Potdar, Anita Mehta, Bhoopendra Sharma, Rohit Beniwal, Rajeev Singh, Amresh Kumar Singh, Vivek Gaur, Mahima Mittal, Gaurav Raj Dwivedi, Sthita Pragnya Behera, Asif Kavathekar, Sanjay Prajapati, Sachin Yadav, Dipti Gautam, Nalin Kumar, Asif Iqbal, Rajni Kant, Manoj Murhekar

“…Out of 943 samples tested, the highest positivity was found for parainfluenza virus [105 (11.13%) PIV-1 (79), PIV-2 (18), PIV-4 (18)], followed by adenovirus [82 (8.7%), RSV-B, [68 (7.21%)], influenza-A [46(4.9%): H1N1 = 29, H3N2 = 14), SARS CoV-2 [28 (3%)], hMPV [13(1.4%), RSV-A [4 (0.42%), and influenza-B (Victoria lineage) 1 (0.10%). …”
Get full text

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised co... by Gabriela Tapia-Calle, Gloria Aguilar, Nathalie Vaissiere, Carla Truyers, Pedro Ylisastigui, Erik Buntinx, Mathieu Le Gars, Frank Struyf, Gert Scheper, Macaya Douoguih, Javier Ruiz-Guiñazú, Robert Patrizi, Wai Ling, Sanne de Ridder, Marit de Groot, Maria Grazia Pau, Gerald Weidinger, Srividya Pradeep, Nadine Salisch, Sophie Cambre

“…Findings: Non-inferiority criteria for concomitant administration in the SD groups were met for SARS-CoV-2 Spike-specific antibodies (ratio 1.11, 95% CI 0.97–1.26) and haemagglutinin inhibition titres for all influenza strains (A/H3N2 1.23, 95% CI 1.05–1.45; B/Victoria 0.99, 95% CI 0.84–1.19; B/Yamagata, 1.03, 95% CI 0.88–1.21) except A/H1N1 (1.28, 95% CI 1.09–1.53) for which the upper limit of the 95% CI was >1.5. …”
Get full text

Safety of influenza vaccination during pregnancy: a systematic review by Brian Hutton, David Moher, Danielle B Rice, Claire Butler, Andrea C Tricco, Becky Skidmore, Candyce Hamel, Chantelle Garritty, Paul A Khan, Marco Ghassemi, Charlene Soobiah, Leila Esmaeilisaraji, Dianna M Wolfe, Deshayne Fell, Mona Hersi, Nadera Ahmadzai, Alan Michaud, Angela Sinilaite

“…Twenty-nine studies (24 cohort and 5 case–control) evaluated seasonal influenza vaccination (trivalent and/or quadrivalent) versus no vaccination and were the focus of our prioritised syntheses; 34 studies of pandemic vaccines (2009 A/H1N1 and others), combinations of pandemic and seasonal vaccines, and seasonal versus seasonal vaccines were also reviewed. …”
Get full text

Delivery of dendritic cells targeting 3M2e-HA2 nanoparticles with a CpG adjuvant via lysosomal escape of Salmonella enhances protection against H9N2 avian influenza virus by Futing Jia, Wenfeng Wang, Yawen Tian, Ainul Zahra, Yingkai He, Chongbo Ge, Tongyu Zhang, Mingyue Wang, Jingshuo Gong, Gerui Zhang, Guilian Yang, Wentao Yang, Chunwei Shi, Jianzhong Wang, Haibin Huang, Xin Cao, Yang Zeng, Nan Wang, Zhannan Wang, Chunfeng Wang, Yanlong Jiang

“…HA2, the neck of the HA protein, and M2e, the extracellular N-terminal structural domain of the M2 protein, are conserved and effective protective antigens.In this study, the HA2 sequences were fused with three M2e copies (H9N2, H1N1 and H5N1) to the norovirus VP1 protein via the SpyTag-SpyCatcher platform to form self-assembled nanoparticles and display antigenic proteins on its surface, yielding pYL262. …”
Get full text